Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.68 |
| ▸ | NOD1 | Q9Y239 | 8/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18571385 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL19034944 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL19034930 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL24249859 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL21110472 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL24249840 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL13694019 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL19034796 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL1758670 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 | |
| SCHEMBL29322995 | 1.00 | GLP1R (0.68) | GLP1RNOD1FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141336-A1 | Pancreatic Peptide Compounds and Use | NOVO NORDISK A/S (DK) | 2015-05-21 | — | — | US | claimed |
| EP-2855517-A1 | PANCREATIC POLYPEPTIDE COMPOUNDS AND USE | Novo Nordisk A/S (DK) | 2015-04-08 | — | — | EP | claimed |
| WO-2013178490-A1 | PANCREATIC POLYPEPTIDE COMPOUNDS AND USE | NOVO NORDISK A/S (DK) | 2013-12-05 | — | — | WO | claimed |
| EP-4729094-A2 | Modulators of complement activity | UCB Holdings, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12558398-B2 | Inflammatory disease treatment with complement inhibitors | UCB HOLDINGS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4218790-B1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250090624-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12239684-B2 | Modulators of complement activity | RA PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4028126-B1 | TREATMENT OF A NEUROLOGICAL DISEASE WITH COMPLEMENT INHIBITORS | RA PHARMACEUTICALS INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20250032574-A1 | NEUROLOGICAL DISEASE TREATMENT WITH ZILUCOPLAN | UCB HOLDINGS, INC. | 2025-01-30 | — | — | US | disclosed |
| US-20240156896-A1 | Modulators of Complement Activity | UCB HOLDINGS, INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2015191951-A2 | MODULATION OF COMPLEMENT ACTIVITY | RA PHARMACEUTICALS, INC. (US) | 2015-12-17 | — | — | WO | disclosed |
| EP-2910569-A1 | Protease stabilized, acylated insulin analogues | Novo Nordisk A/S (DK) | 2015-08-26 | — | — | EP | disclosed |
| EP-2910571-A1 | Protease stabilized, acylated insulin analogues | Novo Nordisk A/S (DK) | 2015-08-26 | — | — | EP | disclosed |
| EP-2910570-A1 | Protease stabilized, acylated insulin analogues | Novo Nordisk A/S (DK) | 2015-08-26 | — | — | EP | disclosed |
| US-20150141336-A1 | Pancreatic Peptide Compounds and Use | NOVO NORDISK A/S (DK) | 2015-05-21 | — | — | US | disclosed |
| US-20150141336-A1 | Pancreatic Peptide Compounds and Use | NOVO NORDISK A/S (DK) | 2015-05-21 | — | — | US | disclosed |
| EP-2855517-A1 | PANCREATIC POLYPEPTIDE COMPOUNDS AND USE | Novo Nordisk A/S (DK) | 2015-04-08 | — | — | EP | disclosed |
| WO-2013178490-A1 | PANCREATIC POLYPEPTIDE COMPOUNDS AND USE | NOVO NORDISK A/S (DK) | 2013-12-05 | — | — | WO | disclosed |
| WO-2013178490-A1 | PANCREATIC POLYPEPTIDE COMPOUNDS AND USE | NOVO NORDISK A/S (DK) | 2013-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032574-A1 | NEUROLOGICAL DISEASE TREATMENT WITH ZILUCOPLAN | ACHE, C5, BCHE | GLP1R 2348/4885NOD1 3583/4885FOLH1 971/4885 |
| US-20150141336-A1 | Pancreatic Peptide Compounds and Use | IAPP, GIPR, SCTR | GLP1R 4/4885NOD1 3107/4885FOLH1 1222/4885 |
| US-20250090624-A1 | MODULATORS OF COMPLEMENT ACTIVITY | C3AR1, C1QBP, C5AR1 | GLP1R 542/4885NOD1 1461/4885FOLH1 973/4885 |
| US-12558398-B2 | Inflammatory disease treatment with complement inhibitors | C5, C1R, SRPRB | GLP1R 4207/4885NOD1 192/4885FOLH1 3146/4885 |
| US-20240156896-A1 | Modulators of Complement Activity | C3AR1, C1QBP, C5AR1 | GLP1R 575/4885NOD1 1517/4885FOLH1 801/4885 |
| US-12239684-B2 | Modulators of complement activity | C3AR1, C1QBP, C5AR1 | GLP1R 575/4885NOD1 1517/4885FOLH1 801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.